MEA Protein Therapeutics Market

MEA Protein Therapeutics Market Size (2023 to 2028)

As per the research report, the Middle East and Africa Protein Therapeutics market size were estimated at USD 14.35 billion in 2023. It is further expected to grow at a CAGR of 5.93% and worth USD 19.14 billion by 2028. It captures 8% of the global market share.

In the UAE, there are over 1 million people diagnosed with diabetes, and 19% of the total population in the UAE is suffering from diabetes. The UAE government has come forward by making some initiatives like arranging campaigns to bring awareness to people regarding the significance of healthy food habits and regular exercise. According to the Dubai Health Authority, multiple projects were launched to help prevent the difficulties caused by diabetes. Visiting hospitals is increasing day-by-day as patients suffer from chronic diseases like diabetes, cancer, and many more. The rising number of Coronavirus cases as there are huge funds in acquiring protein medicines. The above-mentioned factors are driving the growth rate of the market.

However, unfavorable government measures and a hefty administrative framework are expected to impact the protein therapeutics market growth in this region negatively. The costs associated with the treatments are high, which is further estimated to restrain the growth rate. High financial support required to conduct research and develop novel drugs and vaccines is another important factor.

This research report on the MEA protein therapeutics market has been segmented and sub-segmented into the following categories:

By Product:

• Monoclonal Antibodies
• Insulin
• Fusion Protein
• Erythropoietin
• Interferon
• Human Growth Hormone
• Follicle Stimulating Hormone

By Application: 

• Metabolic Disorders
• Immunologic Disorders
• Hematological Disorders
• Cancer
• Hormonal Disorders
• Genetic Disorders
• Others

By Therapeutic Modalities: 

• Protein Diagnostics
• Protein Vaccines
• Protein Therapeutics with Special Targeting Activity
• Protein Therapeutics with Enzymatic Or Regulatory Activity

By Country:  

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

In 2022, Monoclonal antibodies captured the largest market share. It is projected to remain the top leading segment in the forecast period. It is also the market sub-segment, which is anticipated to undergo the fastest growth by 2028.

In 2022, metabolic disorders accounted for the highest market share. However, the cancer market sub-category is predicted to grow the fastest in the forecast period. It is the least attractive market.

Geographically, this region accounted for a market share of 8% in 2019 and is predicted to grow steadily rate during the forecast period. Increasing government initiatives in developing the healthcare sector for the patient's treatment and rising demand for protein therapeutics quickly influences the market. A wide range of research and development activities in the protein engineering sector and developing new drugs and vaccines, and enhancements made for improving healthcare infrastructure are surging the market demand. An increase in sales of protein-based therapeutics is flourishing the growing market demand. UAE and South Africa are the major contributions to the Protein therapeutics market in the Middle East & Africa region.

Rapid developments in biotechnology and protein engineering, enlarging the availability of different protein therapies, a growing number of regular drug approvals towards protein-based therapies, and quick advancements in the medical science field are some factors propelling the market growth. As of 2018, the deaths caused due to colon cancer in UAE were 277, where deaths due to breast cancer were 4.7 thousand in UAE. The government of the UAE has made some initiatives for preventing cancer in the population. Ministry of Health and Prevention is expected to regularly hold breast cancer screening programs to create awareness among the female population. Department of Health-Abu Dhabi suggests people undergo examinations and tests for different types of cancers. The above-mentioned factors are boosting the market growth. The rest of the MEA is projected to have considerable growth in the next five years.

Notable companies playing a leading role in the MEA Protein Therapeutics Market profiled in the report are Baxter International Inc., Eli Lilly, and Company, Abbott Laboratories, Amgen Inc., F. Hoffmann-La Roche Ltd. Other players in the market are Novo Nordisk A/S, Pfizer Inc., Johnson & Johnson, Merck & Co., Inc., and Sanofi.